Comparison of SARS-CoV-2 Antibody Levels after a Third Heterologous and Homologous BNT162b2 Booster Dose
This study aimed to determine the anti-S (receptor binding protein) RBD IgG antibody titers formed against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) and the neutralizing antibody inhibition percentages (nAb IH%) in blood samples taken after two doses of inactive or mRNA-based vacci...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-10-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/10/10/1672 |
| _version_ | 1827647832737185792 |
|---|---|
| author | Nesrin Gareayaghi Mehmet Demirci Dogukan Ozbey Ferhat Dasdemir Harika Oyku Dinc Ilker Inanc Balkan Suat Saribas Neşe Saltoglu Bekir Kocazeybek |
| author_facet | Nesrin Gareayaghi Mehmet Demirci Dogukan Ozbey Ferhat Dasdemir Harika Oyku Dinc Ilker Inanc Balkan Suat Saribas Neşe Saltoglu Bekir Kocazeybek |
| author_sort | Nesrin Gareayaghi |
| collection | DOAJ |
| description | This study aimed to determine the anti-S (receptor binding protein) RBD IgG antibody titers formed against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) and the neutralizing antibody inhibition percentages (nAb IH%) in blood samples taken after two doses of inactive or mRNA-based vaccine and a booster dose. Volunteers with two doses of inactivated CoronaVac (heterologous group; <i>n</i> = 75) and BioNTech (BNT)162b2 mRNA vaccine (homologous group; <i>n</i> = 75) were included in this study. All participants preferred the BNT162b2 vaccine as a booster dose. First, peripheral blood samples were taken 3 months after the second vaccine dose. Second, peripheral blood samples were taken 1 month after the booster dose. Anti-S-RBD IgG titers were determined by CMIA (SARS-CoV-2 IgG II Quant). Neutralizing antibodies were detected by a surrogate neutralization assay (SARS-CoV-2 NeutraLISA, Euroimmun, Lübeck, Germany). The median age of the volunteers was 40 (IQR 29–47) years old. After the heterologous booster dose, anti-S-RBD IgG levels and neutralizing antibodies increased approximately 50-fold and 9-fold, respectively. Anti-S-RBD IgG titers increased by 9 and 57 times, respectively, while nAb IH% increased by 1.5 and 16 times, respectively, among those with heterologous reminder doses and those with and without a prior history of coronavirus disease (COVID-19). This study showed that after the administration of a heterologous booster dose with BNT162b2 to those whose primary vaccination was with inactivated CoronaVac, the binding and neutralizing antibody levels were similar to those who received a homologous BNT162b2 booster dose. It was observed that the administration of heterologous and homologous booster doses resulted in the development of similar levels of neutralizing antibodies, independently from a prior history of COVID-19. |
| first_indexed | 2024-03-09T19:24:07Z |
| format | Article |
| id | doaj.art-9e2045e70508420f8c6872f768242374 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-09T19:24:07Z |
| publishDate | 2022-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-9e2045e70508420f8c6872f7682423742023-11-24T03:04:02ZengMDPI AGVaccines2076-393X2022-10-011010167210.3390/vaccines10101672Comparison of SARS-CoV-2 Antibody Levels after a Third Heterologous and Homologous BNT162b2 Booster DoseNesrin Gareayaghi0Mehmet Demirci1Dogukan Ozbey2Ferhat Dasdemir3Harika Oyku Dinc4Ilker Inanc Balkan5Suat Saribas6Neşe Saltoglu7Bekir Kocazeybek8Blood Center İstanbul Şişli Hamidiye Etfal Training and Research Hospital, 34360 İstanbul, TurkeyDepartment of Medical Microbiology, Medical Faculty, Kırklareli University, 39100 Kırklareli, TurkeyMedical Microbiology Department, Faculty of Medicine, Istanbul Okan University, 34959 İstanbul, TurkeyDepartment of Medical Microbiology, Cerrahpaşa Medical Faculty, Istanbul University-Cerrahpaşa, 34098 Istanbul, TurkeyDepartment of Pharmaceutical Microbiology, Faculty of Pharmacy, Bezmialem Vakıf University, 34098 Istanbul, TurkeyDepartment of Infectious Diseases and Clinical Microbiology, Cerrahpaşa Medical Faculty, Istanbul University-Cerrahpaşa, 34098 Istanbul, TurkeyDepartment of Medical Microbiology, Cerrahpaşa Medical Faculty, Istanbul University-Cerrahpaşa, 34098 Istanbul, TurkeyDepartment of Infectious Diseases and Clinical Microbiology, Cerrahpaşa Medical Faculty, Istanbul University-Cerrahpaşa, 34098 Istanbul, TurkeyDepartment of Medical Microbiology, Cerrahpaşa Medical Faculty, Istanbul University-Cerrahpaşa, 34098 Istanbul, TurkeyThis study aimed to determine the anti-S (receptor binding protein) RBD IgG antibody titers formed against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) and the neutralizing antibody inhibition percentages (nAb IH%) in blood samples taken after two doses of inactive or mRNA-based vaccine and a booster dose. Volunteers with two doses of inactivated CoronaVac (heterologous group; <i>n</i> = 75) and BioNTech (BNT)162b2 mRNA vaccine (homologous group; <i>n</i> = 75) were included in this study. All participants preferred the BNT162b2 vaccine as a booster dose. First, peripheral blood samples were taken 3 months after the second vaccine dose. Second, peripheral blood samples were taken 1 month after the booster dose. Anti-S-RBD IgG titers were determined by CMIA (SARS-CoV-2 IgG II Quant). Neutralizing antibodies were detected by a surrogate neutralization assay (SARS-CoV-2 NeutraLISA, Euroimmun, Lübeck, Germany). The median age of the volunteers was 40 (IQR 29–47) years old. After the heterologous booster dose, anti-S-RBD IgG levels and neutralizing antibodies increased approximately 50-fold and 9-fold, respectively. Anti-S-RBD IgG titers increased by 9 and 57 times, respectively, while nAb IH% increased by 1.5 and 16 times, respectively, among those with heterologous reminder doses and those with and without a prior history of coronavirus disease (COVID-19). This study showed that after the administration of a heterologous booster dose with BNT162b2 to those whose primary vaccination was with inactivated CoronaVac, the binding and neutralizing antibody levels were similar to those who received a homologous BNT162b2 booster dose. It was observed that the administration of heterologous and homologous booster doses resulted in the development of similar levels of neutralizing antibodies, independently from a prior history of COVID-19.https://www.mdpi.com/2076-393X/10/10/1672CoronaVacBNT162b2neutralizing antibodybinding antibody |
| spellingShingle | Nesrin Gareayaghi Mehmet Demirci Dogukan Ozbey Ferhat Dasdemir Harika Oyku Dinc Ilker Inanc Balkan Suat Saribas Neşe Saltoglu Bekir Kocazeybek Comparison of SARS-CoV-2 Antibody Levels after a Third Heterologous and Homologous BNT162b2 Booster Dose Vaccines CoronaVac BNT162b2 neutralizing antibody binding antibody |
| title | Comparison of SARS-CoV-2 Antibody Levels after a Third Heterologous and Homologous BNT162b2 Booster Dose |
| title_full | Comparison of SARS-CoV-2 Antibody Levels after a Third Heterologous and Homologous BNT162b2 Booster Dose |
| title_fullStr | Comparison of SARS-CoV-2 Antibody Levels after a Third Heterologous and Homologous BNT162b2 Booster Dose |
| title_full_unstemmed | Comparison of SARS-CoV-2 Antibody Levels after a Third Heterologous and Homologous BNT162b2 Booster Dose |
| title_short | Comparison of SARS-CoV-2 Antibody Levels after a Third Heterologous and Homologous BNT162b2 Booster Dose |
| title_sort | comparison of sars cov 2 antibody levels after a third heterologous and homologous bnt162b2 booster dose |
| topic | CoronaVac BNT162b2 neutralizing antibody binding antibody |
| url | https://www.mdpi.com/2076-393X/10/10/1672 |
| work_keys_str_mv | AT nesringareayaghi comparisonofsarscov2antibodylevelsafterathirdheterologousandhomologousbnt162b2boosterdose AT mehmetdemirci comparisonofsarscov2antibodylevelsafterathirdheterologousandhomologousbnt162b2boosterdose AT dogukanozbey comparisonofsarscov2antibodylevelsafterathirdheterologousandhomologousbnt162b2boosterdose AT ferhatdasdemir comparisonofsarscov2antibodylevelsafterathirdheterologousandhomologousbnt162b2boosterdose AT harikaoykudinc comparisonofsarscov2antibodylevelsafterathirdheterologousandhomologousbnt162b2boosterdose AT ilkerinancbalkan comparisonofsarscov2antibodylevelsafterathirdheterologousandhomologousbnt162b2boosterdose AT suatsaribas comparisonofsarscov2antibodylevelsafterathirdheterologousandhomologousbnt162b2boosterdose AT nesesaltoglu comparisonofsarscov2antibodylevelsafterathirdheterologousandhomologousbnt162b2boosterdose AT bekirkocazeybek comparisonofsarscov2antibodylevelsafterathirdheterologousandhomologousbnt162b2boosterdose |